Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 83 articles:
HTML format

Single Articles

    August 2021
  1. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Correction to: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:956.

  2. LIANG Y, Ye F, Xu C, Zou L, et al
    A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:943.
    PubMed     Abstract available

  3. WANG X, Guo J, Wang L, Wang M, et al
    Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.
    BMC Cancer. 2021;21:887.
    PubMed     Abstract available

    July 2021
  4. LI J, Cao J, Li P, Yao Z, et al
    Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    BMC Cancer. 2021;21:858.
    PubMed     Abstract available

  5. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    PubMed     Abstract available

  6. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    PubMed     Abstract available

    June 2021
  7. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    PubMed     Abstract available

  8. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    PubMed     Abstract available

    May 2021
  9. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    PubMed     Abstract available

  10. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    PubMed     Abstract available

  11. CHAN LC, Kalyanasundram J, Leong SW, Masarudin MJ, et al
    Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
    BMC Cancer. 2021;21:625.
    PubMed     Abstract available

  12. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available

    April 2021
  13. ZHANG Z, Yu Y, Zhang P, Ma G, et al
    Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    BMC Cancer. 2021;21:458.
    PubMed     Abstract available

  14. MANZANO RG, Catalan-Latorre A, Brugarolas A
    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    BMC Cancer. 2021;21:432.
    PubMed     Abstract available

    March 2021
  15. MIYAKE M, Iida K, Nishimura N, Miyamoto T, et al
    Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    BMC Cancer. 2021;21:266.
    PubMed     Abstract available

  16. CHEN F, Wang Q, Zhou Y
    The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    BMC Cancer. 2021;21:244.
    PubMed     Abstract available

    February 2021
  17. YANG B, Zhao X, Wan C, Ma X, et al
    Genomic profiling of Chinese patients with urothelial carcinoma.
    BMC Cancer. 2021;21:162.
    PubMed     Abstract available

    January 2021
  18. YONEYAMA T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, et al
    Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
    BMC Cancer. 2021;21:72.
    PubMed     Abstract available

  19. PORRECA A, Palmer K, Artibani W, Antonelli A, et al
    Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    BMC Cancer. 2021;21:51.
    PubMed     Abstract available

  20. OKAMURA S, Yoshino H, Kuroshima K, Tsuruda M, et al
    EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    BMC Cancer. 2021;21:48.
    PubMed     Abstract available

    December 2020
  21. KIM TM, Yoo JS, Moon HW, Hur KJ, et al
    Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
    BMC Cancer. 2020;20:1203.
    PubMed     Abstract available

  22. JOHN A, Gunes C, Bolenz C, Vidal-Y-Sy S, et al
    Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface.
    BMC Cancer. 2020;20:1178.
    PubMed     Abstract available

    November 2020
  23. ZHAI M, Tang C, Li M, Chen X, et al
    Short-term mortality risks among patients with non-metastatic bladder cancer.
    BMC Cancer. 2020;20:1148.
    PubMed     Abstract available

    October 2020
  24. LIU B, Sun W, Gao W, Li L, et al
    microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis.
    BMC Cancer. 2020;20:1019.
    PubMed     Abstract available

    September 2020
  25. KOTECHA P, Moss CL, Enting D, Gillett C, et al
    Cohort profile: King's Health Partners bladder cancer biobank.
    BMC Cancer. 2020;20:920.
    PubMed     Abstract available

  26. MATHEUS LHG, Dalmazzo SV, Brito RBO, Pereira LA, et al
    1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
    BMC Cancer. 2020;20:869.
    PubMed     Abstract available

  27. TIAN Z, Meng L, Wang X, Diao T, et al
    Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.
    BMC Cancer. 2020;20:851.
    PubMed     Abstract available

    August 2020
  28. PORSERUD A, Karlsson P, Rydwik E, Aly M, et al
    The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trial.
    BMC Cancer. 2020;20:805.
    PubMed     Abstract available

  29. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available

    June 2020
  30. MAKELA R, Arjonen A, Harma V, Rintanen N, et al
    Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    BMC Cancer. 2020;20:590.
    PubMed     Abstract available

    May 2020
  31. RIPPING TM, Kiemeney LA, van Hoogstraten LMC, Witjes JA, et al
    Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).
    BMC Cancer. 2020;20:455.
    PubMed     Abstract available

    March 2020
  32. ZHANG Y, Ou DH, Zhuang DW, Zheng ZF, et al
    In silico analysis of the immune microenvironment in bladder cancer.
    BMC Cancer. 2020;20:265.
    PubMed     Abstract available

  33. PARKER HG, Dhawan D, Harris AC, Ramos-Vara JA, et al
    RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    BMC Cancer. 2020;20:251.
    PubMed     Abstract available

  34. MORSCH R, Rose M, Maurer A, Cassataro MA, et al
    Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    BMC Cancer. 2020;20:230.
    PubMed     Abstract available

  35. LATIFOVIC L, Villeneuve PJ, Parent ME, Kachuri L, et al
    Silica and asbestos exposure at work and the risk of bladder cancer in Canadian men: a population-based case-control study.
    BMC Cancer. 2020;20:171.
    PubMed     Abstract available

    February 2020
  36. HUPE MC, Dormayer L, Ozimek T, Struck JP, et al
    Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.
    BMC Cancer. 2020;20:140.
    PubMed     Abstract available

    January 2020
  37. SCHMID SC, Koll FJ, Rodel C, Maisch P, et al
    Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
    BMC Cancer. 2020;20:8.
    PubMed     Abstract available

    December 2019
  38. WANG Z, Liu X, Liu X, Sun H, et al
    UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    BMC Cancer. 2019;19:1195.
    PubMed     Abstract available

    November 2019
  39. BOURN J, Rathore K, Donnell R, White W, et al
    Detection of carcinogen-induced bladder cancer by fluorocoxib A.
    BMC Cancer. 2019;19:1152.
    PubMed     Abstract available

  40. MOLENAAR RJ, van Hattum JW, Brummelhuis IS, Oddens JR, et al
    Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:1133.
    PubMed     Abstract available

  41. ZHANG J, Wang Y, Weng H, Wang D, et al
    Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations.
    BMC Cancer. 2019;19:1054.
    PubMed     Abstract available

    October 2019
  42. ALBARAKATI N, Khayyat D, Dallol A, Al-Maghrabi J, et al
    The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer.
    BMC Cancer. 2019;19:991.
    PubMed     Abstract available

    September 2019
  43. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
    BMC Cancer. 2019;19:897.
    PubMed     Abstract available

    August 2019
  44. SASSENBERG M, Droop J, Schulz WA, Dietrich D, et al
    Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    BMC Cancer. 2019;19:806.
    PubMed     Abstract available

  45. FIORENTINO V, Pierconti F, Lenci N, Calicchia M, et al
    Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report.
    BMC Cancer. 2019;19:763.
    PubMed     Abstract available

    July 2019
  46. ZHANG L, Wu B, Zha Z, Qu W, et al
    Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:716.
    PubMed     Abstract available

    June 2019
  47. TRILLA-FUERTES L, Gamez-Pozo A, Prado-Vazquez G, Zapater-Moros A, et al
    Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
    BMC Cancer. 2019;19:636.
    PubMed     Abstract available

  48. ZENG S, Liu A, Dai L, Yu X, et al
    Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
    BMC Cancer. 2019;19:604.
    PubMed     Abstract available

    April 2019
  49. YASUI M, Kawahara T, Izumi K, Yao M, et al
    Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:331.
    PubMed     Abstract available

    March 2019
  50. PANG K, Zhang Z, Hao L, Shi Z, et al
    The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells.
    BMC Cancer. 2019;19:225.
    PubMed     Abstract available

  51. LV S, Wang W, Wang H, Zhu Y, et al
    PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway.
    BMC Cancer. 2019;19:204.
    PubMed     Abstract available

    February 2019
  52. GOULET CR, Champagne A, Bernard G, Vandal D, et al
    Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
    BMC Cancer. 2019;19:137.
    PubMed     Abstract available

    January 2019
  53. AL-HUSSEINI MJ, Kunbaz A, Saad AM, Santos JV, et al
    Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis.
    BMC Cancer. 2019;19:46.
    PubMed     Abstract available

    December 2018
  54. MATHIS C, Lascombe I, Monnien F, Bittard H, et al
    Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
    BMC Cancer. 2018;18:1239.
    PubMed     Abstract available

  55. RACIOPPI M, Di Gianfrancesco L, Ragonese M, Palermo G, et al
    ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    BMC Cancer. 2018;18:1224.
    PubMed     Abstract available

    November 2018
  56. WANG L, Chen S, Zhang Z, Zhang J, et al
    Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer.
    BMC Cancer. 2018;18:1141.
    PubMed     Abstract available

  57. ZHOU T, Li HY, Xie WJ, Zhong Z, et al
    Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.
    BMC Cancer. 2018;18:1088.
    PubMed     Abstract available

  58. WANG Z, Xiao H, Wei G, Zhang N, et al
    Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model.
    BMC Cancer. 2018;18:1108.
    PubMed     Abstract available

    October 2018
  59. STEFFENSEN EH, Cary C, Jensen JB, Larsson H, et al
    Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes.
    BMC Cancer. 2018;18:1035.
    PubMed     Abstract available

    September 2018
  60. WIJBURG CJ, Michels CTJ, Oddens JR, Grutters JPC, et al
    Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study.
    BMC Cancer. 2018;18:861.
    PubMed     Abstract available

    June 2018
  61. LIU H, He W, Wang B, Xu K, et al
    MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    BMC Cancer. 2018;18:659.
    PubMed     Abstract available

  62. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    PubMed     Abstract available

    May 2018
  63. KWON WA, Joung JY, Lim J, Oh CM, et al
    Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea.
    BMC Cancer. 2018;18:617.
    PubMed     Abstract available

  64. XIE H, Zhu Y, Zhang J, Liu Z, et al
    B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    BMC Cancer. 2018;18:590.
    PubMed     Abstract available

    April 2018
  65. MAEDA S, Tomiyasu H, Tsuboi M, Inoue A, et al
    Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
    BMC Cancer. 2018;18:472.
    PubMed     Abstract available

    February 2018
  66. PULIDO M, Roubaud G, Cazeau AL, Mahammedi H, et al
    Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    BMC Cancer. 2018;18:194.
    PubMed     Abstract available

  67. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Oxidative damage and response to Bacillus Calmette-Guerin in bladder cancer cells expressing sialyltransferase ST3GAL1.
    BMC Cancer. 2018;18:198.
    PubMed     Abstract available

    December 2017
  68. ZHANG Z, Zhang G, Gao Z, Li S, et al
    Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    BMC Cancer. 2017;17:861.
    PubMed     Abstract available

    November 2017
  69. HUEBNER D, Rieger C, Bergmann R, Ullrich M, et al
    An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
    BMC Cancer. 2017;17:790.
    PubMed     Abstract available

  70. TAN WS, Feber A, Dong L, Sarpong R, et al
    DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    BMC Cancer. 2017;17:767.
    PubMed     Abstract available

  71. TOLKACH Y, Stahl AF, Niehoff EM, Zhao C, et al
    YRNA expression predicts survival in bladder cancer patients.
    BMC Cancer. 2017;17:749.
    PubMed     Abstract available

    September 2017
  72. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    PubMed     Abstract available

    June 2017
  73. PENG D, Gong YQ, Hao H, He ZS, et al
    Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
    BMC Cancer. 2017;17:391.
    PubMed     Abstract available

    May 2017
  74. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Abstract available

  75. FONTEYNE V, Dirix P, Junius S, Rammant E, et al
    Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
    BMC Cancer. 2017;17:308.
    PubMed     Abstract available

    April 2017
  76. KAO YT, Wu CH, Wu SY, Lan SH, et al
    Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells.
    BMC Cancer. 2017;17:277.
    PubMed     Abstract available

  77. LAVERY HJ, Zaharieva B, McFaddin A, Heerema N, et al
    A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.
    BMC Cancer. 2017;17:247.
    PubMed     Abstract available

    March 2017
  78. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    BMC Cancer. 2017;17:237.
    PubMed     Abstract available

    February 2017
  79. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    PubMed     Abstract available

    January 2017
  80. BAI Y, Wang X, Yang Y, Tang Y, et al
    Parity and bladder cancer risk: a dose-response meta-analysis.
    BMC Cancer. 2017;17:31.
    PubMed     Abstract available

    November 2016
  81. KONG C, Zhan B, Piao C, Zhang Z, et al
    Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice.
    BMC Cancer. 2016;16:892.
    PubMed     Abstract available

  82. BENHAMOU S, Bonastre J, Groussard K, Radvanyi F, et al
    A prospective multicenter study on bladder cancer: the COBLAnCE cohort.
    BMC Cancer. 2016;16:837.
    PubMed     Abstract available

    January 2016
  83. ANANTHARAMAN A, Friedlander T, Lu D, Krupa R, et al
    Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    BMC Cancer. 2016;16:744.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.